Kazia Annual Report 2022

However, the ATM is not a permanent solution and to fulfil its potential, Kazia will need to continue to bring good quality, long-term, fundamentally-driven healthcare investors onto its register. As and when the market reopens, we will waste no opportunity to put the company’s compelling story in front of the widest range of investors we can. In the meantime, however, the access that we have been able to secure to cost-effective and minimally dilutive capital has been vital to our business. CONCLUSION The journey of any biotech company is often circuitous, but we have nevertheless continued to make great progress in the past year. We have two first-class drug candidates in clinical development, with a diverse portfolio of trials that have the potential to open up very substantial commercial markets. We have an experienced and capable team, and an international network of supportive partners and collaborators. In almost every important respect, the fundamentals of Kazia have never been stronger. I would like to thank, once again, my fellow directors and our management team, led by our CEO, James Garner, for their dedication to the company’s work. And, as always, we remain grateful for the ongoing support of our many shareholders, whose faith in the company makes possible everything that we do. Iain Ross Chairman of the Board 5 We believe that paxalisib has great promise, across a wide range of brain cancers, and we remain resolute in the task of demonstrating its potential. Kazia Theraputics Limited Annual Report 2022 2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports Our Collaborators

RkJQdWJsaXNoZXIy MjE2NDg3